News - Eli Lilly

Filter

Current filters:

Eli Lilly

Popular Filters

10 to 34 of 207 results

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

05-03-2014

There was disappointment today for US drug major Eli Lilly and family-owned German pharma firm Boehringer…

Boehringer IngelheimDiabetesEli LillyempagliflozinNorth AmericaPharmaceuticalProductionRegulationUSA

Teva gains approval for generic Evista in the USA

Teva gains approval for generic Evista in the USA

04-03-2014

Israel-based Teva Pharmaceutical Industries says it has received approval from the US Food and Drug Administration…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsNorth AmericaRegulationTeva Pharmaceutical IndustriesUSA

Eli Lilly to expand manufacturing plants in Brazil’s growing pharma market

Eli Lilly to expand manufacturing plants in Brazil’s growing pharma market

03-03-2014

US pharma major Eli Lilly’s subsidiary in Brazil will invest 15 million real ($6.4 million) over the…

BrazilEli LillyPharmaceuticalPricingProductionSouth America

Negative NICE appraisal for Eli Lilly’s Alimta as maintenance therapy

27-02-2014

UK health care guidance body the National Institute for Health and Care Excellence (NICE) has published…

AlimtaEli LillyNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

Eli Lilly’s ramucirumab Ph III lung cancer trial meets primary endpoint

Eli Lilly’s ramucirumab Ph III lung cancer trial meets primary endpoint

19-02-2014

US pharma major Eli Lilly has revealed that the REVEL trial showed that its ramucirumab improved survival…

Eli LillyOncologyPharmaceuticalramucirumabResearch

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector

17-02-2014

The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

Systemic psoriasis market forecast to reach $10.4 billion by 2020

05-02-2014

The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Sanofi sues Eli Lilly over Lantus patent infringement

Sanofi sues Eli Lilly over Lantus patent infringement

31-01-2014

French drug major Sanofi says it has filed a patent infringement suit against USA pharma firm Eli Lilly…

BiosimilarsDiabetesEli LillyLantusLegalNorth AmericaPatentsPharmaceuticalSanofiUSA

Eli Lilly sales beat forecasts, despite 2% decline

Eli Lilly sales beat forecasts, despite 2% decline

30-01-2014

US pharma major Eli Lilly has reported financial results, showing that global sales in the fourth quarter…

Eli LillyFinancialPharmaceutical

Lilly buys back CGRP antibody for migraine prevention from Arteaus Therapeutics

Lilly buys back CGRP antibody for migraine prevention from Arteaus Therapeutics

13-01-2014

Based on positive Phase II data, US drug major Eli Lilly has acquired all development rights for a calcitonin…

Arteaus TherapeuticsEli LillyLicensingLY2951742NeurologicalPharmaceutical

Eli Lilly forecasts 2014 earnings decline, in line with expectations

Eli Lilly forecasts 2014 earnings decline, in line with expectations

07-01-2014

US drug major Eli Lilly, ahead of reporting fourth-quarter/full year 2013 results later this month, has…

Eli LillyFinancialPharmaceutical

Atherothrombotic diseases market to grow to $47 billion in 2022

Atherothrombotic diseases market to grow to $47 billion in 2022

23-12-2013

The launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies…

AstraZenecaBayerBrilintaCardio-vascularEli LillyevacetrapibGlobalMarkets & MarketingPharmaceuticalXarelto

Global insulin market expanded to $20.8 billion in 2012

17-12-2013

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular…

Asia-PacificBayerChinaDiabetesEli LillyGlobalMarkets & MarketingNovo NordiskSanofi

UK Dementia Consortium to bridge the gap between academia and pharma

UK Dementia Consortium to bridge the gap between academia and pharma

11-12-2013

The UK has today announced a new £3 million ($4.9 million) Dementia Consortium bringing together research…

EisaiEli LillyNeurologicalPharmaceuticalPoliticsResearchUK

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

10-12-2013

Demographics favor the continued strong growth in the diabetes care market, and independent investment…

DiabetesEli LillyFinancialMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Eli Lilly drops edivoxetine as adjunctive therapy for MDD

Eli Lilly drops edivoxetine as adjunctive therapy for MDD

06-12-2013

Given that results from three late-stage studies of edivoxetine did not meet the primary study objective…

edivoxetineEli LillyNeurologicalPharmaceutical

Survey aims to discover how early diabetes diagnoses can aid better outcomes

Survey aims to discover how early diabetes diagnoses can aid better outcomes

02-12-2013

A multinational survey of more than 10,000 people with type 2 diabetes has been launched by German family-owned…

Boehringer IngelheimDiabetesEli LillyGlobalPharmaceuticalResearch

10 to 34 of 207 results

Back to top